Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Expert Opin Orphan Drugs. 2016 Jul 31;4(9):961–970. doi: 10.1080/21678707.2016.1215910

Figure 3. Modifications to the benzamide scaffold create molecules with isoform selectivity.

Figure 3

The structure of HDACi 109 is shown, indicating the positions of the benzamide ring that can be modified to afford isotype selectivity (R1, R2) and the fold differences in HDAC inhibitory activity for selective compounds are shown at the right.